Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Elizabeth Medhurst"'
Autor:
Haidar Al Saffar, Alice Thomson, Jo‐Lynn S. Tan, Qiwei Wang, Emma Birch, Samantha Koschel, Elizabeth Medhurst, Dale Jobson, Sean Ong, Daniel A. Moon, Declan Murphy, Nathan Lawrentschuk
Publikováno v:
BJUI Compass, Vol 5, Iss 4, Pp 497-505 (2024)
Abstract Introduction and Objectives Patient‐centred (PC) and holistic care improves patient satisfaction and health outcomes. We sought to investigate the benefit of utilising a PC pathology report in patients undergoing radical prostatectomy (RP)
Externí odkaz:
https://doaj.org/article/fe12572287e445289fd9d026653fa71f
Autor:
Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson, James P. Buteau, Declan G. Murphy, Brian Kelly, Lavinia Spain, Shahneen Sandhu, Arun A. Azad, Elizabeth Medhurst, Grace Kong, Michael S. Hofman
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Reported here is a case of rapidly progressive metastatic castration-resistant prostate cancer treated with [ 177 Lu]Lu-PSMA-617 in the setting of severe renal impairment and impending ureteric obstruction. PSMA is expressed on renal tubular cells, r
Externí odkaz:
https://doaj.org/article/d046a9f4e7954988a4fbdf23c77fed17
Autor:
Heidi Fettke, Louise Kostos, James Buteau, Jason A. Steen, Elizabeth Medhurst, Mo B. Haskali, Declan Murphy, Maria Docanto, Patricia Bukczynska, Nicole Ng, Shahneen Sandhu, Siavash Foroughi, Luc Furic, Tu Nguyen-Dumont, Michael S. Hofman, Arun A. Azad
Publikováno v:
Cancer Research. 83:5614-5614
[177Lu]Lu-PSMA-617 (LuPSMA) radionuclide therapy improves overall survival in mCRPC, and was recently approved by the FDA. Nevertheless, owing to the heterogeneous nature of mCRPC, responses to LuPSMA therapy can be variable, and resistance is inevit
Autor:
James Patrick Buteau, Louise Kathleen Kostos, Ramin Alipour, Price Jackson, Lachlan McIntosh, Brittany Emmerson, Mohammad B Haskali, Theresa Yeung, Sophia Xie, Elizabeth Medhurst, Rajeev Ravi, Brian D. Gonzalez, Heidi Fettke, Nicole Ng, Maria Docanto, Patricia Bukczynska, Benjamin Blyth, Luc Furic, Arun Azad, Michael S Hofman
Publikováno v:
Journal of Clinical Oncology. 41:TPS281-TPS281
TPS281 Background: [177Lu]Lu-PSMA is an effective class of therapy for men with metastatic castration-resistant prostate cancer (mCRPC); however, progression is inevitable. The limited durability of response is partially explained by the presence of
Autor:
Louise Kathleen Kostos, William Yu Ching Lai, Peter Lambroglou, Elizabeth Medhurst, James Patrick Buteau, Shahneen Sandhu, Ben Tran, Lavinia Anne Spain, Ciara Conduit, Roslyn Wallace, Ramin Alipour, Timothy J. Akhurst, Grace Kong, Anthony Cardin, Javad Saghebi, Aravind Ravi Kumar, Michael S Hofman, Arun Azad
Publikováno v:
Journal of Clinical Oncology. 41:77-77
77 Background: [177Lu]Lu-PSMA (LuPSMA) is currently FDA-approved for use in the post-taxane, post-antiandrogen setting in pts with mCRPC. Little is known about the efficacy of treatment in pts with subsequent progression after LuPSMA. In this single-
Autor:
Heidi Fettke, Nicole Ng, Christine Hauser, Patricia Bukczynska, Elizabeth Medhurst, Louise Kostos, James Buteau, Jason Steen, Tu Nguyen-Dumont, Michael Hofman, Arun A. Azad
Publikováno v:
Cancer Research. 82:532-532
Recent clinical trials have revealed that Lutetium PSMA-617 (Lu-PSMA, a small molecular inhibitor of prostate-specific membrane antigen radiolabelled with the beta emitter 177-Lutetium) significantly improves clinical outcomes including overall survi
Autor:
Elizabeth Medhurst, Jonathan O’Brien, Nathan Lawrentschuk, Sean Ong, Arun Azad, Declan G. Murphy
Publikováno v:
Transl Androl Urol
Prostate cancer continues to be one of the most commonly diagnosed cancers in men globally and a leading cause of male cancer deaths. The landscape of metastatic hormone-sensitive prostate cancer has significantly changed over the past decade. For ma